#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Ovarian cancer Dementia Alzheimer's type Colorectal cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Malignant melanoma Non-small cell lung cancer metastatic Asthma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Fatty acid oxidation disorder Cortical dysplasia Hypereosinophilic syndrome Mucopolysaccharidosis I Langerhans cell sarcoma Ischaemic stroke Meningococcal immunisation C3 glomerulopathy Multifocal motor neuropathy Marfan's syndrome Adenovirus infection Breast cancer Anti-neutrophil cytoplasmic antibody positive vasculitis Fibrosarcoma Adrenogenital syndrome More trials…

    Learn about Rare Diseases

    Wiskott-Aldrich syndrome – Life with Disease Kearns-Sayre syndrome – Treatment Adrenogenital syndrome – Treatment Mucous membrane pemphigoid – Life with Disease Haemolytic uraemic syndrome – Diagnostics Lymphangiosarcoma – Diagnostics Mucopolysaccharidosis I Undifferentiated sarcoma – Life with Disease Breast angiosarcoma metastatic – Life with Disease Rosai-Dorfman syndrome – Trials in Disease More diseases…
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Padeliporfin Imiquimod Clavulanic Acid Damoctocog Alfa Pegol Methylprednisolone Florbetapir (18F) Human Albumin Solution Satralizumab 64CU-PSMA I&T Anidulafungin Sym024 Doxycycline Hyclate Alks 2680 TUVATEXIB Clomifene Citrate Verapamil Hydrochloride Oregovomab Hydroxocobalamin Pelareorep Sodium Nitroprusside Dihydrate More therapies…

    Learn about Your Condition

    Myxofibrosarcoma Petit mal epilepsy Food allergy Congenital aplastic anaemia Arthroscopy Blood disorder High-grade B-cell lymphoma Adenocarcinoma of colon Retroperitoneal fibrosis Cachexia Anal cancer Extraskeletal ossification Pulmonary sarcoidosis Obsessive-compulsive disorder Thyroid cancer metastatic More diseases…
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Jean Perrin

Centre Jean Perrin

58 Rue Montalembert, Clermont Ferrand, 63000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Lomustine with or without Additional Brain Radiation for Patients with Recurrent Glioblastoma

    Recruiting

    3 1 1 1
    Investigated diseases:
    • Glioblastoma
    Austria Belgium Czechia Denmark France Germany +4

  • Study on the Safety of Using Chemoradiation with Cisplatin and Carboplatin for Early-Stage Vulvar Cancer Patients with Macrometastasis in Sentinel Lymph Node

    Recruiting

    2 1 1 1
    Investigated drugs:
    • Carboplatin
    • Cisplatin
    Belgium France The Netherlands Sweden

  • Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

    Recruiting

    3 1 1
    Investigated drugs:
    • Darolutamide
    • Abiraterone Acetate
    • Enzalutamide
    Austria Belgium Finland France Germany Hungary +5

  • Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy and Chemotherapy

    Recruiting

    3 1 1 1
    Investigated drugs:
    • Fludrocortisone
    • Fludrocortisone Acetate
    • Opevesostat Tosilate
    Austria Czechia Denmark Finland France Germany +8

  • Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy

    Recruiting

    3 1 1 1
    Investigated drugs:
    • Fludrocortisone
    • Fludrocortisone Acetate
    • Opevesostat Tosilate
    Czechia Estonia France Germany Greece Hungary +9

  • Study of Dostarlimab for Patients with Advanced or Metastatic Non-Colorectal/Non-Endometrial Cancer with dMMR/MSI, Compared to Standard Drug Combination

    Recruiting

    2 1 1 1
    Investigated diseases:
    • Neoplasm
    Investigated drugs:
    • Mitotane
    • Trabectedin
    • Ifosfamide
    France

  • Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

    Recruiting

    3 1 1 1
    Investigated drugs:
    • Goserelin Acetate
    • Op-1250
    • PALAZESTRANT
    Austria Belgium Bulgaria Czechia France Germany +7

  • Study on the Safety and Effects of [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 in Patients with Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1 1
    Investigated diseases:
    • Clear cell renal cell carcinoma
    • Colorectal cancer
    • Ductal adenocarcinoma of pancreas
    Investigated drugs:
    • 177Lu-Dpi-4452
    • 68Ga-Dpi-4452
    • Acetazolamide
    Belgium France

  • Study on the Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    • Apalutamide
    • Gozetotide
    • Lutetium (177Lu) Vipivotide Tetraxetan
    Belgium France Ireland Italy The Netherlands Spain

  • Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

    Recruiting

    3 1 1 1
    Investigated diseases:
    • Renal cell carcinoma
    Investigated drugs:
    • Cabozantinib
    • Axitinib
    • Ipilimumab
    Austria Belgium Czechia Denmark Finland France +4
Previous Page
1 … 4 5 6 7 8 … 19
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!